Nasdaq:US$15.05 (-0.05) | HKEX:HK$23.55 (-0.20) | AIM:£2.27 (+0.08)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer